

Paper NHSE180709

# **BOARD PAPER - NHS ENGLAND**

Title: Procurement controls committee report

Clearance: Paul Baumann: Chief Financial Officer

#### Purpose of paper:

• Report from the procurement controls committee (PCC), in accordance with its terms of reference

#### Key issues and recommendations:

The Committee met seven times in the period, approving 22 business cases without conditions and 27 with conditions prior to submission to the Department of Health (DH) for onward approval.

Work with DH to streamline approval procedures, and thus ensure an appropriate balance of tight control and responsiveness to need, is continuing.

#### Actions required by Board Members:

• The Board is asked to note the work of the committee

# **Procurement Controls Committee Report**

- 1. The objective of the committee is to approve expenditure on activities relating to NHS England's functions that are subject to DH and Cabinet Office controls utilising, where appropriate, the delegated financial limits set out in the Standing Financial Instructions for members in attendance (the committee has no delegated budgetary authority of its own).
- 2. Following the establishment of the finance & investment committee (FIC), the PCC is focused on approval of short term revenue business cases, with FIC scrutinising long term commitments, capital and property related business cases as well as wider issues of financial policy, performance and budgetary control.

Dates	Number Cases on Agenda	Number of Cases Approved	Number of Cases with Conditions	Number of Cases Rejected
11/04/2013	2	1	0	1
18/04/2013	3	2	0	1
03/05/2013	11	3	8	0
16/05/2013	7	1	6	0
30/05/2013	11	9	1	1
20/06/2013	15	3	11	1
27/06/2013	4	3	1	0
Total	53	22	27	4

The number of cases considered at each meeting, and their outcome is as follows:

3. Work is ongoing with the DH to ensure a consistent and efficient application of the controls appropriate to a major Arms Length Body (and specifically the requirements for NHS England, DH, Ministerial and/or Cabinet Office approval). This has shown dividends, with welcome steps to rationalise key processes and approval flows, but at the time of writing we still await written confirmation of the agreed position from DH.

### Paul Baumann

### Chief Financial Officer

July 2013